PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
Growthphenylephrine hydrochloride injection, solution
NDAINTRAVENOUSSOLUTION
Approved
May 2025
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
3/8 — Basic
PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE (phenylephrine hydrochloride injection, solution) by Dr. Reddy's Laboratories is adrenergic alpha1-agonists [moa]. First approved in 2025.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Phenylephrine hydrochloride injection is an alpha-1 adrenergic agonist administered intravenously as a solution in 0.9% sodium chloride. It works by stimulating alpha-1 adrenergic receptors to produce vasoconstriction and increase blood pressure. This product is used in acute care settings to manage hypotensive episodes in hospitalized patients.
Growth18.1 years to LOE
Recently approved IV product in growth phase with no current competitive pressure, positioning early-stage commercialization teams to establish market presence.
Mechanism of Action
Adrenergic alpha1-Agonists
Pharmacologic Class:
alpha-1 Adrenergic Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This recently approved IV product represents an early-stage growth opportunity with minimal current job market visibility, suggesting roles will emerge as Dr. Reddy's scales commercialization. Working on this product offers the chance to build a brand from launch in the competitive vasopressor market with 18+ years of patent protection.
Brand Manager
Worked on PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.